FDA Generic Drug Approval and the ANDA Process

The Abbreviated New Drug Application (ANDA) is the regulatory mechanism through which manufacturers obtain FDA authorization to market a generic version of a previously approved drug. This page covers how the ANDA process works, the standards a generic drug must meet, the scenarios that trigger different review pathways, and the decision boundaries that distinguish approvable from non-approvable submissions. Understanding this process matters because generic drugs account for approximately 90% of all prescriptions dispensed in the United States, according to the FDA Center for Drug Evaluation and Research (CDER).

Definition and scope

An ANDA is a formal application submitted to FDA's Center for Drug Evaluation and Research requesting approval to manufacture and distribute a drug product that is therapeutically equivalent to a previously approved brand-name (reference listed drug, or RLD). Unlike a New Drug Application (NDA), the ANDA does not require the applicant to independently establish safety and effectiveness through original clinical trials. Instead, the applicant relies on FDA's prior finding that the RLD is safe and effective — a statutory shortcut established by the Drug Price Competition and Patent Term Restoration Act of 1984, commonly called the Hatch-Waxman Act (21 U.S.C. § 355(j)).

The ANDA pathway is administered under 21 C.F.R. Part 314, Subpart C. It applies to small-molecule drugs; biologics follow a distinct pathway under the Biologics Price Competition and Innovation Act of 2009, handled through the FDA Biologics License Application process. The full landscape of FDA drug oversight is described at FDA Drug Approval Process.

The core requirement for ANDA approval is that the proposed generic be bioequivalent to the RLD — meaning it delivers the same active ingredient to the same site of action at the same rate and to the same extent under the same conditions. Bioequivalence is typically demonstrated when the 90% confidence interval for the ratio of the generic's pharmacokinetic parameters (AUC and Cmax) to those of the RLD falls within the 80–125% acceptance window (FDA Guidance for Industry: Bioequivalence Studies with Pharmacokinetic Endpoints).

How it works

The ANDA submission and review process follows a defined sequence:

1. Reference Listed Drug identification — The applicant identifies the RLD from FDA's Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations), which lists approved drugs, their patent expiration dates, and any regulatory exclusivity periods.
2. Patent certification — Under Hatch-Waxman, the applicant files one of four patent certifications (Paragraph I through Paragraph IV) regarding each patent listed for the RLD. A Paragraph IV certification — asserting the listed patent is invalid or will not be infringed — triggers a mandatory 45-day window during which the patent holder may file an infringement suit, automatically staying FDA approval for up to 30 months (21 U.S.C. § 355(j)(5)(B)(iii)).
3. Bioequivalence study data — The applicant submits data from in vivo or in vitro studies demonstrating bioequivalence under FDA-recognized methodologies.
4. Chemistry, Manufacturing, and Controls (CMC) documentation — Full specifications for the drug's composition, manufacturing process, and Good Manufacturing Practice compliance are required.
5. Labeling — The proposed labeling must be identical to the RLD's approved labeling except for differences attributable to different manufacturer, inactive ingredients, or patent/exclusivity-protected conditions of use (21 C.F.R. § 314.94(a)(8)).
6. FDA review and facility inspection — CDER reviews the application and may inspect the manufacturing facility. FDA assigns an action date under the Generic Drug User Fee Amendments (GDUFA), which set target review timelines — 10 months for standard applications and 8 months for priority applications (FDA GDUFA Reauthorization Performance Goals).
7. Approval or Complete Response Letter (CRL) — If the application is approvable, FDA issues an approval letter. If deficiencies exist, FDA issues a CRL specifying what must be addressed before approval can be granted.

Common scenarios

First-to-file exclusivity — The first applicant to file an ANDA with a Paragraph IV certification is eligible for 180 days of marketing exclusivity. During this window, FDA cannot approve a second ANDA for the same drug (21 U.S.C. § 355(j)(5)(B)(iv)). This incentive drives significant competitive activity around branded drug patent cliffs.

Citizen petitions as delay mechanisms — Brand manufacturers sometimes file citizen petitions with FDA requesting that the agency impose additional approval requirements on a pending ANDA. FDA is statutorily required to respond to such petitions no later than 150 days after receipt, and the agency cannot delay final approval solely on the basis of a pending petition (21 U.S.C. § 355(q)).

Complex drugs and 505(b)(2) overlap — Products with complex formulations — such as topical gels, inhalation products, or transdermal patches — may not qualify for a standard ANDA because bioequivalence cannot be established through pharmacokinetic studies alone. FDA publishes product-specific bioequivalence guidance for such drugs. Some applicants instead pursue a 505(b)(2) application, which falls between a full NDA and an ANDA.

Regulatory exclusivity blocking periods — Even after patent expiration, a generic ANDA may be blocked by statutory exclusivity periods: 5 years for new chemical entities, 3 years for new clinical investigation exclusivity, and 7 years for orphan drug designation (21 U.S.C. § 355(c)(3)).

Decision boundaries

FDA applies distinct standards when evaluating whether an ANDA can receive an approval versus a complete response:

Bioequivalence acceptance vs. failure — The 80–125% confidence interval window is a bright-line standard. Applications that cannot demonstrate bioequivalence within this range are not approvable absent a waiver or alternative methodology accepted by FDA for a specific product.

Therapeutic equivalence rating distinctions — FDA's Orange Book assigns therapeutic equivalence (TE) codes to approved generics. An "A" rating (e.g., AB, AT, AN) indicates the product is therapeutically equivalent to the RLD and may be substituted at the pharmacy level in all 50 states. A "B" rating indicates the product is not considered therapeutically equivalent, blocking automatic substitution. The distinction turns on whether any actual or potential bioequivalence problem has been identified.

Standard vs. priority ANDA review — FDA designates certain ANDAs for priority review when the application is for a drug on the drug shortage list or when the application is the sole ANDA submitted for a product. Priority designation shortens the target action date from 10 months to 8 months under GDUFA II performance commitments.

Manufacturing deficiency thresholds — A facility that receives an Official Action Indicated (OAI) classification following an FDA inspection will not receive ANDA approval until the deficiencies are resolved. This threshold operates independently of the scientific review — a scientifically adequate application is still blocked by unresolved manufacturing deficiencies.

The broader context of FDA's regulatory authority over drugs, including how the agency's mandate is structured, is covered at fdaauthority.com.